Should you buy these FTSE surgers and sliders?

Royston Wild takes a look at two London stocks making waves in Tuesday business.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Shares in Nanoco (LSE: NANO) have taken a pummelling in Tuesday trade, the stock last 10% lower after releasing a less-than-appetising trading update.

The quantum dot specialist advised that full-year revenues for the period to July 2016 slipped 77% to £470,000, a result that caused pre-tax losses to widen to £12.6m from £10.88m a year earlier.

This is the second hefty share price fall in less than seven days, Nanoco advising last week that it had deferred licence fee royalties, with £500,000 to be booked for the year to July 2017 and £700,000 over the following six years.

Regardless of these roadblocks, Nanoco remains confident that its transformed business model should deliver stunning sales growth in the years ahead. The company has inked major contract agreements with the likes of Merck and Wah Hong in recent months, for example, assisted by its terrific record of innovation — Nanoco’s IP portfolio consisted of 467 patents and patents pending as of July 2016.

And the Mancunian business has stepped up manufacturing capacity to speed up returns from its cutting-edge technology.

These measures should push Nanoco into the black from this year, at least according to City forecasts, and earnings of 1.3p per share are currently forecast.

Value hunters will no doubt be put off by a subsequent P/E rating of 41.9 times, soaring above the benchmark of 15 times broadly considered reasonable value. Still, those seeking stocks with potentially-explosive long-term earnings potential could do a lot worse than to check out Nanoco.

Too soon?

Victrex (LSE: VCT) has enjoyed a more pleasant ride so far in Tuesday’s session, with a mostly-positive trading update pushing investor demand up 7% from last night’s close. The polymer manufacturer is now dealing at fresh 10-month peaks.

But first the bad news. Victrex said that total revenues slipped 4% to £252.3m in the 12 months to September 2016, with declining demand at its Consumer Electronics unit pressing down on the top line. Yet Victrex has suggested that things are starting to look up, the company advising of “an improved performance in the second half and a good finish to 2016.”

Critically the business has seen conditions stabilise in the Oil & Gas division, it noted, while its Aerospace and Automotive arms have also been “performing well.” And volumes at Consumer Electronics more than doubled during April-September from the previous six months.

But investors should refrain from breaking out the bunting just yet, Victrex warning that “our early planning assumption suggests Consumer Electronics volumes will be significantly lower in 2017.” And of course demand from the fossil fuel sector could also deteriorate again should pressure on oil producers’ capex budgets persist.

The City expects Victrex to register a 7% earnings bounce in fiscal 2017, resulting in a P/E rating of 18.6 times. Considering that the firm’s core operations aren’t quite out of the woods, I reckon cautious investors should sit on the sidelines for the time being.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Royston Wild has no position in any shares mentioned. The Motley Fool UK has recommended Victrex. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Publish Test

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing Articles

JP P-Press Update Test

Read more »

Investing Articles

JP Test as Author

Test content.

Read more »

Investing Articles

KM Test Post 2

Read more »

Investing Articles

JP Test PP Status

Test content. Test headline

Read more »

Investing Articles

KM Test Post

This is my content.

Read more »

Investing Articles

JP Tag Test

Read more »

Investing Articles

Testing testing one two three

Sample paragraph here, testing, test duplicate

Read more »